Montreal, June 9, 2021 - Morphocell announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.

​

Dr. Massimiliano Paganelli, the company's co-founder and CEO, will present Morpohocell's ReLiver technology and its applications for the treatment of severe liver disease. ReLiver is a unique stem cell-derived human engineered liver tissue capable of fully mature liver function. Dr. Paganelli will show efficacy and safety preclinical data supporting the ongoing development of ReLiver as an allogeneic cell therapy product to treat acute and acute-on-chronic liver failure. The presentation will be available to registered attendees from 9 am ET June 10.

​

Attendees at BIO Digital will be able to view Morphocell’s Company Presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14.  To meet with us at BIO Digital, you can find registration information here.

​

​

About Morphocell Technologies

Morphocell Technologies is a preclinical regenerative medicine company focused on the commercialization of innovative stem cell therapies aimed at treating severe liver disease. Morphocell is developing an extensive therapeutic platform based on its allogeneic pluripotent stem cell-derived engineered liver tissues. www.morphocell.com

​

​

About BIO
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.